These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 18774637)

  • 1. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
    Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
    Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma.
    Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H
    Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
    Tevaarwerk AJ; Kolesar JM
    Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib, a dual EGFR and HER2 kinase inhibitor, selectively inhibits HER2-amplified human gastric cancer cells and is synergistic with trastuzumab in vitro and in vivo.
    Wainberg ZA; Anghel A; Desai AJ; Ayala R; Luo T; Safran B; Fejzo MS; Hecht JR; Slamon DJ; Finn RS
    Clin Cancer Res; 2010 Mar; 16(5):1509-19. PubMed ID: 20179222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor.
    Witters LM; Witkoski A; Planas-Silva MD; Berger M; Viallet J; Lipton A
    Oncol Rep; 2007 Feb; 17(2):465-9. PubMed ID: 17203189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer.
    Nam HJ; Kim HP; Yoon YK; Hur HS; Song SH; Kim MS; Lee GS; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
    Cancer Lett; 2011 Mar; 302(2):155-65. PubMed ID: 21306821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The dual ErbB1/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogen-dependent gene expression in antiestrogen-resistant breast cancer.
    Chu I; Blackwell K; Chen S; Slingerland J
    Cancer Res; 2005 Jan; 65(1):18-25. PubMed ID: 15665275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
    Wong TW; Lee FY; Yu C; Luo FR; Oppenheimer S; Zhang H; Smykla RA; Mastalerz H; Fink BE; Hunt JT; Gavai AV; Vite GD
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6186-93. PubMed ID: 17062696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines.
    Olaussen KA; Commo F; Tailler M; Lacroix L; Vitale I; Raza SQ; Richon C; Dessen P; Lazar V; Soria JC; Kroemer G
    Oncogene; 2009 Dec; 28(48):4249-60. PubMed ID: 19749798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
    McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
    J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
    Gilmer TM; Cable L; Alligood K; Rusnak D; Spehar G; Gallagher KT; Woldu E; Carter HL; Truesdale AT; Shewchuk L; Wood ER
    Cancer Res; 2008 Jan; 68(2):571-9. PubMed ID: 18199554
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
    Reid A; Vidal L; Shaw H; de Bono J
    Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of the mTOR/S6K signal is necessary to enhance fluorouracil-induced apoptosis in gastric cancer cells with HER2 amplification.
    Tomioka H; Mukohara T; Kataoka Y; Ekyalongo RC; Funakoshi Y; Imai Y; Kiyota N; Fujiwara Y; Minami H
    Int J Oncol; 2012 Aug; 41(2):551-8. PubMed ID: 22614071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The characterization of novel, dual ErbB-2/EGFR, tyrosine kinase inhibitors: potential therapy for cancer.
    Rusnak DW; Affleck K; Cockerill SG; Stubberfield C; Harris R; Page M; Smith KJ; Guntrip SB; Carter MC; Shaw RJ; Jowett A; Stables J; Topley P; Wood ER; Brignola PS; Kadwell SH; Reep BR; Mullin RJ; Alligood KJ; Keith BR; Crosby RM; Murray DM; Knight WB; Gilmer TM; Lackey K
    Cancer Res; 2001 Oct; 61(19):7196-203. PubMed ID: 11585755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
    Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
    Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
    Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
    J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel dual EGFR/HER2 inhibitor KU004 induces cell cycle arrest and apoptosis in HER2-overexpressing cancer cells.
    Tian C; Ding P; Yuan Z; Li H; Zhao Y; Sun L; Guo Q; Wang Z; Sun L; Zhang L; Jiang Z
    Apoptosis; 2015 Dec; 20(12):1599-612. PubMed ID: 26437915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
    Trowe T; Boukouvala S; Calkins K; Cutler RE; Fong R; Funke R; Gendreau SB; Kim YD; Miller N; Woolfrey JR; Vysotskaia V; Yang JP; Gerritsen ME; Matthews DJ; Lamb P; Heuer TS
    Clin Cancer Res; 2008 Apr; 14(8):2465-75. PubMed ID: 18413839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.